Targeting the p53 pathway in retinoblastoma with subconjunctival nutlin-3a

Cancer Research

Volumn 71, Issue 12, 2011, Pages 4205-4213

  Brennan, Rachel C ^a   Federico, Sara ^a   Bradley, Cori ^a   Zhang, Jiakun ^a   Flores Otero, Jacqueline ^a   Wilson, Matthew ^b   Stewart, Clinton ^a   Zhu, Fangyi ^a   Guy, Kip ^a   Dyer, Michael A ^a,b,c  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^c HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CREMOPHOR; ETOPOSIDE; NUTLIN 3; POLOXAMER; PROTEIN MDM2; PROTEIN MDMX; PROTEIN P53; TOPOTECAN; VINCRISTINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; AREA UNDER THE CURVE; ARTICLE; BLOOD EYE BARRIER; CELL DEATH; CONTROLLED STUDY; DRUG EFFICACY; DRUG PENETRATION; DRUG SOLUBILITY; ENUCLEATION; HISTOPATHOLOGY; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; LEUKOCYTE COUNT; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN TARGETING; RETINOBLASTOMA; VISUAL ACUITY;

ANIMALS; CONJUNCTIVA; DISEASE MODELS, ANIMAL; HUMANS; IMIDAZOLES; INTRAOCULAR PRESSURE; MICE; MICE, INBRED C57BL; MICE, SCID; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-MDM2; RETINAL NEOPLASMS; RETINOBLASTOMA; SOLUBILITY; TUMOR SUPPRESSOR PROTEIN P53; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79958811171     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-11-0058     Document Type: Article

References (17)

1. Shields CL, Shields JA. Diagnosis and management of retinoblastoma. Cancer Control 2004;11:317-27. (Pubitemid 40310587)
2. Rodriguez-Galindo C, Wilson MW, Chantada G, Fu L, Qaddoumi I, Antoneli C, et al. Retinoblastoma: one world, one vision. Pediatrics 2008;122:e763-70.
3. Rodriguez-Galindo C, Wilson MW, Haik BG, Merchant TE, Billups CA, Shah N, et al. Treatment of intraocular retinoblastoma with vincristine and carboplatin. J Clin Oncol 2003;21:2019-25. (Pubitemid 46606392)
4. Abramson DH, Frank CM, Dunkle IJ. A phase I/II study of subconjunctival carboplatin for intraocular retinoblastoma. Ophthalmology 1999;106:1947-50.
5. Chantada GL, Fandino AC, Carcaboso AM, Lagomarsino E, de Davila MT, Guitter MR, et al. A phase I study of periocular topotecan in children with intraocular retinoblastoma. Invest Ophthalmol Vis Sci 2009;50:1492-6.
6. Nemeth KM, Federico S, Carcaboso AM, Shen Y, Schaiquevich P, Zhang J, et al. Subconjunctival carboplatin and systemic topotecan treatment in preclinical models of retinoblastoma. Cancer 2011; 117:421-34.
7. Mcevoy J, Flores-Otero J, Zhang J, Nemeth K, Brennan R, Bradley C, et al. Coexpression of normally incompatible developmental pathways in retinoblastoma genesis. Cancer Cell 2011; In Press.
8. Laurie NA, Donovan SL, Shih CS, Zhang J, Mills N, Fuller C, et al. Inactivation of the p53 pathway in retinoblastoma. Nature 2006; 444:61-6. (Pubitemid 44684754)
9. Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z, et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004;303:844-8.
10. Elison JR, Cobrinik D, Claros N, Abramson DH, Lee TC. Small molecule inhibition of HDM2 leads to p53-mediated cell death in retinoblastoma cells. Arch Ophthalmol 2006;124:1269-75. (Pubitemid 44379861)
11. Bai F, Zhu F, Tagen M, Miller L, Owens TS, Mallari J, et al. Determination of nutlin-3a in murine plasma by liquid chromatography electrospray ionization tandem mass spectrometry (LC-ESI-MS/MS). J Pharm Biomed Anal 2010;51:915-20.
12. Zhang F, Tagen M, Throm S, Mallari J, Miller L, Guy RK, et al. Whole body physiologically-based pharmacokinetic model for Nutlin-3a in mice after intravenous and oral administration. Drug Metab Dispos 2011;39:15-21.
13. Zhang J, Schweers B, Dyer MA. The first knockout mouse model of retinoblastoma. Cell Cycle 2004;3:952-9. (Pubitemid 40185382)
14. Laurie NA, Gray JK, Zhang J, Leggas M, Relling M, Egorin M, et al. Topotecan combination chemotherapy in two new rodent models of retinoblastoma. Clin Cancer Res 2005;11: 7569-78. (Pubitemid 41507720)
15. Reed CA, Mayhew CN, McClendon AK, Knudsen ES. Unique impact of RB loss on hepatic proliferation: tumorigenic stresses uncover distinct pathways of cell cycle control. J Biol Chem; 285: 1089-96.
16. Vousden KH, Lu X. Live or let die: the cell's response to p53. Nat Rev Cancer 2002;2:594-604. (Pubitemid 37328926)
17. Michaelis M, Rothweiler F, Klassert D, von Deimling A, Weber K, Fehse B, et al. Reversal of P-glycoprotein-mediated multidrug resistance by the murine double minute 2 antagonist nutlin-3. Cancer Res 2009; 69:416-21.